the placebo group – Page 9 – Communicable Diseases Research

Effect of a Single High-Dose Vitamin D 3 on the Length of Hospital Stay of Severely 25-Hydroxyvitamin D-Deficient Patients with COVID-19

Randomized Controlled Trial

Published on 2021-11-172022-10-04
Journal: Clinics [Category] MERS, SARS, 임상,

Efficacy and Safety of Ergoferon in Children from 6 Months to 6 Years Old with Acute Respiratory Viral Infections in Contemporary Outpatient Practice: A Multicenter, Double-Blind, Placebo-Controlled Randomized Trial

Research Article

Published on 2021-11-152022-10-31
Journal: Canadian Respiratory Journal [Category] COVID-19, SARS,

[키워드] Acute respiratory infection adverse event AEs Antibiotics antibody Antiviral ARI being CD4 children clinical trial Combination disease double-blind effective Effectiveness Efficacy and safety evaluate Fever Frequency IMPROVE incidence increase Infant Infectious disease intention-to-treat analysis interferon gamma International Mild moderate modulate molecular target Month multicenter nonspecific oral temperature outcome measure outcomes Outpatient parallel-group Patient patients Placebo placebo group placebo-controlled Randomized Rash recovered patients reduced respiratory Safety Secondary endpoints severity significantly lower Symptom symptom severity score symptomatic Symptoms the mean the patient the placebo group the primary endpoint therapy time Treatment virus was performed Year
[DOI] 10.1155/2021/5570178 PMC 바로가기 [Article Type] Research Article

Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial

Randomized Controlled Trial

Published on 2021-11-022022-10-05
Journal: JAMA [Category] 임상,

[키워드] 95% CI adaptive all-cause mortality Analysis anticipated Anticoagulant antiplatelet antithrombotic therapy Aspirin benefit bleeding event Cardiopulmonary clinical Clinical outcome clinically conducted COVID-19 diagnosis to randomization did not reduce dose double-blind Effect Efficacy end point Enrollment event rate Final finding Follow-up glomerular filtration rate greater groups Hospitalization Hospitalized initiated Inpatient Intervention median age median time monitoring board Myocardial infarction occurred outcome Outpatient participant Patient Placebo placebo-controlled trial Platelet prevention primary end point Prophylactic random allocation randomization Randomized randomized patient receive reduce required risk risk difference STABLE stroke symptomatic the placebo group therapeutic therapy Thromboembolism Treatment Trial trial medication venous with COVID-19 women
[DOI] 10.1001/jama.2021.17272 PMC 바로가기 [Article Type] Randomized Controlled Trial

Do we need bamlanivimab? Is etesevimab a key to treating Covid-19?

밤라니비맙이 필요한가요? 에테세비맙이 코로나19 치료의 핵심인가?

Article

Published on 2021-11-012022-09-11
Journal: Expert opinion on biological therapy [Category] MERS, SARS, 변종, 진단,

The effect of BCG revaccination on all-cause mortality beyond infancy: 30-year follow-up of a population-based, double-blind, randomised placebo-controlled trial in Malawi

유아기를 넘어서 모든 원인 사망률에 대한 BCG 재검토의 효과 : 말라위에서 인구 기반, 이중 맹검, 무작위 위약 대조 시험의 30 년 추적 관찰

Randomized Controlled Trial

Published on 2021-11-012022-08-13
Journal: The Lancet. Infectious Diseases [Category] MERS, SARS, 비임상, 임상, 한센병,

[키워드] Adults age all-cause mortality Analysis assigned BCG BCG vaccination breath cause children death deaths District double-blind Effect enrolled Evidence evidence of finding Follow-up funding Glaxo-strain In-vitro individual infancy Infant Infants information LEPRA leprosy Mortality no difference non-infectious non-specific participant per 1000 person-year Placebo placebo group placebo recipient placebo recipients placebo-controlled trial Prevent prevention proportion randomised randomised controlled Randomly receive recipient recorded reduce relief revaccination risk severity of COVID-19 Sex Surveillance survival survival analysis the District the placebo group time interval Trial Tuberculosis vaccination Wellcome Trust were recorded Year
[DOI] 10.1016/S1473-3099(20)30994-4 PMC 바로가기 [Article Type] Randomized Controlled Trial

Adverse events of active and placebo groups in SARS-CoV-2 vaccine randomized trials: A systematic review

Research Paper

Published on 2021-10-282022-10-30
Journal: The Lancet Regional Health - Europe [Category] COVID-19,

[키워드] Ad26.COV2.S Adenovirus adopted Adverse adverse event adverse events AEs approved BNT162b2 clinical trial clinical trials database Effect Effects event fatigue favor finding first dose funding group groups headache identify in both group injection local pain mRNA mRNA vaccines mRNA-1273 mRNA-based myalgia nocebo effect Occurrence Pain Participants Placebo placebo group placebo recipient placebo recipients Randomized Randomized control trials Reactions recipients regulatory agencies Relative risk reported Safety assessment SARS-CoV-2 vaccine SARS-CoV-2 vaccines systematic review the placebo group the vaccine Vaccine with COVID-19
[DOI] 10.1016/j.lanepe.2021.100253 PMC 바로가기 [Article Type] Research Paper

Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19

경증 또는 중등도의 Covid-19에서 밤라니비맙과 에테세비맙

Clinical Trial

Published on 2021-10-072022-09-12
Journal: The New England Journal of Medicine [Category] MERS, SARS, 신약개발, 임상, 진단,

[키워드] 1:1 95% CI 95% confidence interval accelerated acute respiratory syndrome Administered age ambulatory patient ambulatory patients assigned bamlanivimab baseline clinical status Cohort Combination complications coronavirus death defined develop Diagnosis Disease progression etesevimab greater high risk Hospitalization Immunity incidence increased risk Infection investigator Laboratory limit log medical condition Mild moderate NCT04427501 Neutralizing occurred passive immunity Patient patients phase 3 trial Placebo Primary outcome progression provide randomization Randomly receive reduction risk SARS-CoV-2 severe coronavirus disease severe disease single intravenous infusion the patient the placebo group the SARS-CoV-2 Treatment Trial Viral load women
[DOI] 10.1056/NEJMoa2102685 PMC 바로가기 [Article Type] Clinical Trial

Use of an antiviral mouthwash as a barrier measure in the SARS-CoV-2 transmission in adults with asymptomatic to mild COVID-19: a multicentre, randomized, double-blind controlled trial

무증상에서 경증의 COVID-19가 있는 성인의 SARS-CoV-2 전파에 대한 차단 수단으로 항바이러스 구강 세정제 사용: 다기관, 무작위, 이중 맹검 대조 시험

Randomized Controlled Trial

Published on 2021-10-012022-09-11
Journal: Clinical microbiology and infection : the official [Category] SARS, 임상, 치료기술, 치료제,

[키워드] 1:1 acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 antiviral mouthwash appear assigned asymptomatic to mild benefit Citrox Controlled trial coronavirus coronavirus disease Coronavirus disease 2019 Course COVID-19 cyclodextrin decrease demonstrated detect determine disease dose double-blind effective eligible patient first dose greater initial intention-to-treat analysis IQR log median median value Mouthwash multicentre PCR-positive patient per-protocol analysis performed Placebo placebo group Quantitative RT-PCR Randomized Randomized controlled trial Randomly recruited reduce reducing Saliva salivary SARS-CoV-2 SARS-CoV-2 viral load second dose severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 significantly more Support Symptom the placebo group the SARS-CoV-2 Transmission treat Trial Viral load was performed was used β-cyclodextrin.
[DOI] 10.1016/j.cmi.2021.05.028 PMC 바로가기 [Article Type] Randomized Controlled Trial

Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine

AZD1222(ChAdOx1 nCoV-19) 코로나19 백신 3상 안전성 및 효능

Clinical Trial

Published on 2021-09-292022-09-25
Journal: The New England Journal of Medicine [Category] Fulltext, SARS, 신약개발, 임상, 진단, 치료법,

[키워드] 95% CI 95% confidence interval acute respiratory syndrome Adults adverse event age Analysis antibody AstraZeneca AZD1222 binding ChAdOx1 nCoV-19 clinical trial coronavirus Critical dose double-blind Efficacy first dose generally mild in both groups incidence increased risk Infection investigated Local moderate neutralizing antibody nucleocapsid Older participant Participants phase Phase 3 Placebo placebo-controlled Population randomization Randomized receive Result Safe Safety SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 spike protein second dose Seroconversion severe coronavirus disease subgroups symptomatic symptomatic COVID-19 systemic reaction the placebo group The United States Vaccine
[DOI] 10.1056/NEJMoa2105290 PMC 바로가기 [Article Type] Clinical Trial

Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19

코로나19 예방을 위한 피하 REGEN-COV 항체 조합

Randomized Controlled Trial

Published on 2021-09-232022-09-12
Journal: The New England Journal of Medicine [Category] MERS, SARS, 임상, 진단, 치료법,

[키워드] 1:1 acute respiratory syndrome Administered age assigned Asymptomatic Combination Contact coronavirus coronavirus disease death diagnosis of SARS-CoV-2 diagnostic dose efficacy end point enrolled high risk Hospitalization household contact Immunity Infection Local matching placebo monoclonal antibody participant Participants Placebo Prevent prevented randomization Randomly receive reduce reduced REGEN-COV Regeneron Pharmaceutical REGN-CoV2 resolution of symptom risk risk reduction SARS-CoV-2 SARS-COV-2 infection Seronegativity shown stratified Subcutaneous subcutaneous injection subsequent symptomatic symptomatic and asymptomatic symptomatic COVID-19 symptomatic disease symptomatic SARS-CoV-2 infection the median the placebo group toxic effect uninfected Viral load
[DOI] 10.1056/NEJMoa2109682 PMC 바로가기 [Article Type] Randomized Controlled Trial